Open AccessReview of Doravirine Resistance Patterns Identified in Participants During Clinical Development
Author(s) -
Elizabeth A. Martin,
MingTain Lai,
Winnie Ngo,
Meizhen Feng,
Donald J. Graham,
Daria J. Hazuda,
Sushma Kumar,
Carey Hwang,
Peter Sklar,
Ernest AsanteAppiah
Publication year - 2020
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002496
Subject(s) - resistance (ecology) , medicine , psychology , biology , ecology
Doravirine (DOR) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) approved for the treatment of HIV-1 infection in patients with no known DOR resistance-associated mutations. DOR was rationally designed to address limitations associated with other approved NNRTIs, particularly resistance from common NNRTI resistance-associated mutants containing K103N, Y181C, or G190A reverse transcriptase substitutions.